Last reviewed · How we verify
Ophthalmic Insert — Competitive Intelligence Brief
phase 3
Ophthalmic insert / sustained-release device
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Ophthalmic Insert (Ophthalmic Insert) — Ocular Therapeutix, Inc.. An ophthalmic insert that delivers medication directly to the eye to treat ocular surface disease and inflammation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ophthalmic Insert TARGET | Ophthalmic Insert | Ocular Therapeutix, Inc. | phase 3 | Ophthalmic insert / sustained-release device |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Ophthalmic insert / sustained-release device class)
- Ocular Therapeutix, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ophthalmic Insert CI watch — RSS
- Ophthalmic Insert CI watch — Atom
- Ophthalmic Insert CI watch — JSON
- Ophthalmic Insert alone — RSS
- Whole Ophthalmic insert / sustained-release device class — RSS
Cite this brief
Drug Landscape (2026). Ophthalmic Insert — Competitive Intelligence Brief. https://druglandscape.com/ci/ophthalmic-insert. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab